Psychedelic Alpha

Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our leadproductcandidate,lysergidetartrate(ourproprietary orally disintegrating tablet form oflysergide(LSD) D-tartrate),represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided bythe recognitionthat patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to addresstheunderlying causes of psychiatric and neurological disorders. By turning...